Analysts’ Recent Ratings Updates for Artiva Biotherapeutics (ARTV)

Several analysts have recently updated their ratings and price targets for Artiva Biotherapeutics (NASDAQ: ARTV):

• 10/31/2026 – Artiva Biotherapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/29/2026 – Artiva Biotherapeutics was downgraded by Jefferies Financial Group from “buy” to “hold”. They now have a $4.00 price target on the stock.
• 10/27/2026 – Artiva Biotherapeutics was downgraded by TD Cowen from “buy” to “hold”.
• 10/27/2026 – Artiva Biotherapeutics was downgraded by Needham & Company LLC from “buy” to “hold”.
• 10/27/2026 – Artiva Biotherapeutics was downgraded by Wedbush from “outperform” to “neutral”. They now have a $4.00 price target on the stock.
• 10/19/2026 – Artiva Biotherapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/2/2026 – Artiva Biotherapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 10/2/2026 – Artiva Biotherapeutics had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $40.00 price target on the stock.

Artiva Biotherapeutics Stock Down 2.1%

Shares of Artiva Biotherapeutics stock opened at $4.13 on Friday. Artiva Biotherapeutics, Inc. has a twelve month low of $2.96 and a twelve month high of $14.53. The company has a 50-day simple moving average of $7.53 and a two-hundred day simple moving average of $7.95. The stock has a market capitalization of $201.92 million, a price-to-earnings ratio of -1.25 and a beta of 2.67.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.63). On average, sell-side analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.71 earnings per share for the current fiscal year.

Insider Buying and Selling at Artiva Biotherapeutics

In other news, COO Jennifer Bush sold 8,370 shares of Artiva Biotherapeutics stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $6.84, for a total value of $57,250.80. Following the completion of the sale, the chief operating officer directly owned 366,159 shares in the company, valued at approximately $2,504,527.56. The trade was a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Fred Aslan sold 23,463 shares of the firm’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $7.20, for a total transaction of $168,933.60. Following the transaction, the chief executive officer directly owned 1,519,606 shares of the company’s stock, valued at $10,941,163.20. The trade was a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 137,048 shares of company stock valued at $1,086,167 in the last three months. Corporate insiders own 1.80% of the company’s stock.

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is intended to provide readily available cell-based treatments that can be manufactured in advance and administered without using each patient’s own cells.

Artiva’s lead product candidate is AlloNK, also known as AB-101, an allogeneic NK cell therapy derived from umbilical cord blood. The company is evaluating AlloNK in combination with antibody treatments, including rituximab, for conditions such as B-cell malignancies and autoimmune diseases.